FDA
-
-
-
-
-
-
-
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
-
-
-
-
-
-
-
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Prelude Therapeutics (PRLD) Announces IND Clearance for PRT2527, Highly Selective CDK9 Inhibitor
-
-
-
334,273 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


